title: [Research status on molecular targeted therapy for squamous-cell lung cancer].
abstract: Lung cancer is one of the world's highest morbidity and mortality disease in malignant tumors currently. Squamous-cell lung cancer (SQCLC) is one of the most prevalent subtypes of lung cancer worldwide, after surgery, radiotherapy, chemotherapy and other comprehensive treatment, its 5-year survival rate is still below 15%. The current molecular targeted therapy plays an important role in the treatment of SQCLC, an urgent need to be more in-depth study. SQCLC molecular targeted therapy mainly epidermal growth factor receptor (EGFR), phosphoin-3-kinase catalytic alpha polypeptide (PIK3CA), fibroblast growth factor receptor 1 (FGFR1), discoidin domain receptor 2 (DDR2), phosphatase and tensin homolog deleted on chromosome ten (PTEN), BRAF, MET, insulin-like growth factor 1 receptor (IGF-1R) and other as the target of the drug, some targeted drugs are being developed, and some targeted drugs have entered clinical trials. In recent years, with studies molecular targeted therapy in SQCLC, analysis of the development and trgeted therapy achieved substantial progress in improving the survival rate of SQCLC, and other research to improve the quality of life, make is possible to individualized targeted therapy of SQCLC.
authors.affiliation: Department of Medical Oncology, China Meitan General Hospital, Beijing 100028, China.
authors.forename: Yanan
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Medical Oncology, China Meitan General Hospital, Beijing 100028, China.
authors.forename: Yunzhi
authors.initials: Y
authors.lastname: Zhou
authors.affiliation: Department of Medical Oncology, China Meitan General Hospital, Beijing 100028, China.
authors.forename: Hongwu
authors.initials: H
authors.lastname: Wang
mesh_terms: D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D058990:Molecular Targeted Therapy / Q000379:methods*